Back to Search

BASSEL EL-RAYES, MD

MD

Medical Oncology Physician

NPI: 1437196433IndividualAccepts Medicare

Specialties, Licenses & Credentials

Hematology (Internal Medicine) Physician

Internal Medicine — Hematology

Code: 207RH0000X

4301069026(MI)C206694(CA)
Hematology & Oncology Physician

Internal Medicine — Hematology & Oncology

Code: 207RH0003X

44198(AL)
Internal Medicine Physician

Internal Medicine

Code: 207R00000X

4301069026(MI)
Medical Oncology PhysicianPrimary

Internal Medicine — Medical Oncology

Code: 207RX0202X

062977(GA)C206694(CA)4301069026(MI)

CMS Specialties

PrimaryMEDICAL ONCOLOGY

Education

OTHER

Class of 1996

Research & Publications (20)

Protein kinase C: a target for therapy in pancreatic cancer.
PMID 18437080·Pancreas·2008
8-other
Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer.
PMID 17429629·Cancer Chemother Pharmacol·2008
3-trial
A phase I study of gemcitabine and uracil-ftorfar (UFT)/leucovorin.
PMID 17414457·Am J Clin Oncol·2007
3-trial
A phase I study of flavopiridol and docetaxel.
PMID 16683073·Invest New Drugs·2006
3-trial
Phase I study of bryostatin 1 and gemcitabine.
PMID 17145828·Clin Cancer Res·2006
3-trial
Phase I study of liposomal doxorubicin (Doxil) and cyclophosphamide in solid tumors.
PMID 15528981·Invest New Drugs·2005
3-trial
A phase II study of celecoxib, gemcitabine, and cisplatin in advanced pancreatic cancer.
PMID 16034525·Invest New Drugs·2005
3-trial
A phase II study of carboplatin and paclitaxel in adenocarcinoma of unknown primary.
PMID 15803009·Am J Clin Oncol·2005
3-trial
Cellular DNA content parameters as prognostic indicators in human astrocytomas.
PMID 15690121·J Neurooncol·2005
4-observational
Pseudoaneuploid subpopulations detected in normal upper aerodigestive tract mucosa consistent with physiological apoptosis in normally differentiating squamous mucosa.
PMID 15523439·Otolaryngol Head Neck Surg·2004
8-other
Cyclooxygenase-2-dependent and -independent effects of celecoxib in pancreatic cancer cell lines.
PMID 15542781·Mol Cancer Ther·2004
8-other
Targeting the epidermal growth factor receptor.
PMID 15238978·Br J Cancer·2004
6-review
A phase II study of carboplatin and paclitaxel in esophageal cancer.
PMID 15151955·Ann Oncol·2004
3-trial
Hormone-refractory prostate cancer responding to capecitabine.
PMID 12597973·Urology·2003
5-case
Cytochrome p450 and glutathione transferase expression in human breast cancer.
PMID 12738724·Clin Cancer Res·2003
4-observational
A review of systemic therapy for advanced pancreatic cancer.
PMID 16258429·Clin Adv Hematol Oncol·2003
6-review
Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
PMID 12885810·J Clin Oncol·2003
3-trial
Developments in the systemic therapy of pancreatic cancer.
PMID 12643012·Cancer Invest·2003
6-review
Comparison of DNA content parameters in paired, fresh tissue pretreatment biopsies and surgical resections from squamous cell carcinoma of the head and neck.
PMID 12601310·Otolaryngol Head Neck Surg·2003
4-observational
Hormonal therapy for prostate cancer: past, present and future.
PMID 12113064·Expert Rev Anticancer Ther·2002
6-review

Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.

Contact & Hours

Via practice · 5 locations total

Address
500 22nd St S
Birmingham, AL 35233

Locations (5)

Practice Location

500 22nd St S, Birmingham, AL
(205) 801-8415

Practice Location

4100 JOHN R, DETROIT, MI
(800) 527-6266

Practice Location

9400 CAMPUS POINT DR, LA JOLLA, CA
(800) 926-8273

Practice Location

3855 HEALTH SCIENCES DR, LA JOLLA, CA
(800) 926-8273

Practice Location

200 W ARBOR DR, SAN DIEGO, CA
(800) 926-8273

Quick Facts

NPI
1437196433
Entity Type
Individual
Gender
Male
Medicare
Accepted
Specialties
7
Locations
5
Years in Practice
30
Publications
20

Are you this provider?

Claim Your Profile